Dosing and switching strategies for quetiapine fumarate

Clinical Therapeutics
Andrew J CutlerJohn A Tumas

Abstract

The atypical antipsychotic agent quetiapine fumarate has demonstrated efficacy and tolerability in clinical trials in patients with chronic or subchronic exacerbations of schizophrenic symptoms. This review summarizes clinical trial data and other practical information regarding the initiation and routine administration of quetiapine. Appropriate strategies for switching from other antipsychotic agents to quetiapine are also discussed. Quetiapine is an appropriate initial treatment for psychotic disturbances in patients with schizophrenia of any stage and for those in whom a therapeutic switch is indicated for clinical reasons, such as inability to tolerate the side effects of treatment. Titration to 400 mg/d is recommended using the following schedule, administered BID in divided doses: day 1, 50 mg; day 2, 100 mg: day 3, 200 mg; day 4, 300 mg; and day 5, 400 mg. In patients who respond to quetiapine, therapy should be continued at the optimal dose that maintains remission, within the range of 150 to 750 mg/d. When a change in therapy is indicated, several strategies for switching from one antipsychotic agent to another may be applied to switching to quetiapine. Whereas studies have shown that an abrupt switch to or withdrawal...Continue Reading

References

Jan 1, 1995·Schizophrenia Bulletin·D ShoreJ A Lieberman
Jul 15, 1993·The New England Journal of Medicine·J M AlvirJ A Schaaf
May 1, 1996·Biological Psychiatry·N Tanríverdi, K M Yazící
Jan 1, 1996·The British Journal of Psychiatry : the Journal of Mental Science·S Bazire
Sep 1, 1996·Biological Psychiatry·E StipC Link
Jan 1, 1996·Schizophrenia Bulletin·T M ShiovitzN R Cutler
Jun 1, 1997·The Journal of Clinical Psychiatry·J K StanillaG M Simpson
Nov 14, 1997·Acta Psychiatrica Scandinavica·J Peuskens, C G Link
May 29, 1999·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezM Rosenfeld
Jun 11, 1999·Journal of Affective Disorders·T SuppesR M Post
Feb 1, 2000·Journal of Clinical Psychopharmacology·S D Targum, J L Abbott
Mar 30, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·C Stanniland, D Taylor
Jun 1, 2000·Movement Disorders : Official Journal of the Movement Disorder Society·H H FernandezB P Abbott
Aug 25, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·P T ThyrumC Yeh
Sep 27, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Zaudig
Oct 26, 2000·Clinical Therapeutics·P N TariotI W Rak
Feb 24, 2001·Journal of Clinical Psychopharmacology·Y W WongP T Thyrum
Aug 8, 2001·The Journal of Clinical Psychiatry·R NarendranJ J Grace
Aug 21, 2001·Clinical Pharmacokinetics·C L DeVane, C B Nemeroff
Oct 30, 2001·The Journal of Clinical Psychiatry·M SajatovicC R Bingham
Jan 31, 2002·The Journal of Clinical Psychiatry·E VietaUNKNOWN Group for the Study of Risperidone in Affective Disorders (GSRAD)
Mar 23, 2002·Journal of Clinical Psychopharmacology·Steven G PotkinLisa A Arvanitis
Jul 3, 2007·Psychiatric Services : a Journal of the American Psychiatric Association·Julie KreyenbuhlMark Olfson

❮ Previous
Next ❯

Citations

Dec 1, 2004·Acta Neuropsychiatrica·Pierre ChueLili Kopala
Jul 20, 2005·Primary Care Companion to the Journal of Clinical Psychiatry·Prakash S Masand
Dec 2, 2006·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Josep Maria HaroUNKNOWN SOHO Study Group
Sep 14, 2010·Journal of Clinical Pharmacy and Therapeutics·B-J Chae
Dec 2, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Joseph Peuskens
Aug 11, 2005·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Frank GianfrancescoJacqueline Pesa
Jul 1, 2012·Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society·Kaliaperumal KrishnarajDuraikannu Manikandan
Aug 3, 2006·Journal of Psychiatric Practice·Glenn W CurrierEdwin van Wijngaarden
Jul 14, 2005·Journal of Clinical Psychopharmacology·Mark A SmithMartin Brecher
Jul 13, 2006·Expert Review of Neurotherapeutics·Chanoch Miodownik, Vladimir Lerner
May 29, 2008·Expert Review of Neurotherapeutics·David Suarez, Josep Maria Haro
Jan 4, 2017·Journal of Pharmaceutics·Ahmed Mahmoud Abdelhaleem Ali, Mayyas Mohammad Ahmad Al-Remawi
Jan 1, 2003·International Journal of Psychiatry in Clinical Practice·A De NayerCa Altman
Dec 21, 2005·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Howard C MargoleseLawrence Annable
Nov 3, 2016·The Mental Health Clinician·Chelsea N CarrTerrence Bradley Baugh
Mar 7, 2021·Brain Sciences·Isis Gil-MiravetGonzalo Haro

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here